Citi: MEDBOT-B (02252) Last Year's Revenue Growth Exceeded Expectations; Fee Standardization Policy Marks Industry Milestone

Stock News01-22

According to a research report released by Citi, MEDBOT-B (02252) issued a strong positive profit alert for the 2025 fiscal year, guiding for a year-on-year revenue increase of 110% to 120%. This surpassed the bank's expectation of a 100% rise and the market consensus of a 94% increase. The bank views the revenue beat as a key highlight, confirming that the company is in a phase of rapid global business expansion, with revenue growth being the most critical metric for investors. Citi maintains a "Buy" rating on MEDBOT with a target price of HK$32. The report mentioned that this momentum is primarily driven by overseas orders for the "Tumai" robot surging to over 100 units in the 2025 fiscal year, exceeding the August guidance of 70 to 80 units, thereby providing excellent visibility for revenue conversion in the 2026 fiscal year. The market reacted positively on January 21st to the newly released national "Guidelines for Establishing Price Items for Pathology-related Medical Services (Trial)". Shares of MEDBOT and its peers rose. The bank considers this policy a milestone, as it reduces the risks associated with the commercialization path and provides a clear, unified framework for industry growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193339147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193339147","market":"hk","top_or_hot":-1,"title":"Citi: MEDBOT-B (02252) Last Year's Revenue Growth Exceeded Expectations; Fee Standardization Policy Marks Industry Milestone","media":"Stock News","content":"<p>According to a research report released by Citi, MEDBOT-B (02252) issued a strong positive profit alert for the 2025 fiscal year, guiding for a year-on-year revenue increase of 110% to 120%. This surpassed the bank's expectation of a 100% rise and the market consensus of a 94% increase. The bank views the revenue beat as a key highlight, confirming that the company is in a phase of rapid global business expansion, with revenue growth being the most critical metric for investors. Citi maintains a \"Buy\" rating on MEDBOT with a target price of HK$32.\nThe report mentioned that this momentum is primarily driven by overseas orders for the \"Tumai\" robot surging to over 100 units in the 2025 fiscal year, exceeding the August guidance of 70 to 80 units, thereby providing excellent visibility for revenue conversion in the 2026 fiscal year.\nThe market reacted positively on January 21st to the newly released national \"Guidelines for Establishing Price Items for Pathology-related Medical Services (Trial)\". Shares of MEDBOT and its peers rose. The bank considers this policy a milestone, as it reduces the risks associated with the commercialization path and provides a clear, unified framework for industry growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citi: MEDBOT-B (02252) Last Year's Revenue Growth Exceeded Expectations; Fee Standardization Policy Marks Industry Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCiti: MEDBOT-B (02252) Last Year's Revenue Growth Exceeded Expectations; Fee Standardization Policy Marks Industry Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-22 14:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a research report released by Citi, MEDBOT-B (02252) issued a strong positive profit alert for the 2025 fiscal year, guiding for a year-on-year revenue increase of 110% to 120%. This surpassed the bank's expectation of a 100% rise and the market consensus of a 94% increase. The bank views the revenue beat as a key highlight, confirming that the company is in a phase of rapid global business expansion, with revenue growth being the most critical metric for investors. Citi maintains a \"Buy\" rating on MEDBOT with a target price of HK$32.\nThe report mentioned that this momentum is primarily driven by overseas orders for the \"Tumai\" robot surging to over 100 units in the 2025 fiscal year, exceeding the August guidance of 70 to 80 units, thereby providing excellent visibility for revenue conversion in the 2026 fiscal year.\nThe market reacted positively on January 21st to the newly released national \"Guidelines for Establishing Price Items for Pathology-related Medical Services (Trial)\". Shares of MEDBOT and its peers rose. The bank considers this policy a milestone, as it reduces the risks associated with the commercialization path and provides a clear, unified framework for industry growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4207","symbol_name":"综合性银行","start_time":0,"source_url":"","article_id":"1193339147","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193339147","pubTimestamp":1769064860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a research report released by Citi, MEDBOT-B (02252) issued a strong positive profit alert for the 2025 fiscal year, guiding for a year-on-year revenue increase of 110% to 120%. This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4207":"综合性银行","BK1617":"AI医疗","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK1100":"医疗保健设备","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","C":"花旗","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4566":"资本集团","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4504":"桥水持仓","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4559":"巴菲特持仓","02252":"微创机器人-B","BK4588":"碎股","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC"},"translate_title":"花旗：MEDBOT-B(02252)去年营收增长超预期；收费标准化政策标志行业里程碑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1,"C":1},"content_text":"According to a research report released by Citi, MEDBOT-B (02252) issued a strong positive profit alert for the 2025 fiscal year, guiding for a year-on-year revenue increase of 110% to 120%. This surpassed the bank's expectation of a 100% rise and the market consensus of a 94% increase. The bank views the revenue beat as a key highlight, confirming that the company is in a phase of rapid global business expansion, with revenue growth being the most critical metric for investors. Citi maintains a \"Buy\" rating on MEDBOT with a target price of HK$32.\nThe report mentioned that this momentum is primarily driven by overseas orders for the \"Tumai\" robot surging to over 100 units in the 2025 fiscal year, exceeding the August guidance of 70 to 80 units, thereby providing excellent visibility for revenue conversion in the 2026 fiscal year.\nThe market reacted positively on January 21st to the newly released national \"Guidelines for Establishing Price Items for Pathology-related Medical Services (Trial)\". Shares of MEDBOT and its peers rose. The bank considers this policy a milestone, as it reduces the risks associated with the commercialization path and provides a clear, unified framework for industry growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193339147","isCrawlerRequest":true}